Notice2026-04532
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 9, 2026
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the invention listed below, which is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 45 (Monday, March 9, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 45 (Monday, March 9, 2026)]
[Notices]
[Pages 11329-11330]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-04532]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Allergy and Infectious Diseases
(NIAID), an institute of the National Institutes of Health (NIH),
Department of Health and Human Services (HHS), is giving notice of the
invention listed below, which is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Inquiries related to this licensing
opportunity should be directed to: Chris Kornak at 240-565-2632, or
<a href="/cdn-cgi/l/email-protection#53303b213a207d383c213d3238133d3a3b7d343c25"><span class="__cf_email__" data-cfemail="5e3d362c372d7035312c303f351e30373670393128">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Novel malaria vaccine candidates comprising engineered
nanoparticles.
Description of Technology
Using proteins derived from the malaria Plasmodium falciparum
parasite, NIAID has developed three different nanoparticle platforms to
serve as scaffolds for displaying multiple copies of malaria antigens
in an organized, repetitive manner to enhance vaccine effectiveness.
The first platform uses the pyridoxal 5'-phosphate (PLP) synthase
protein to form a nanoparticle displaying 48 copies of up to 4
different proteins. The second platform uses the chaperone 60 (Cpn60),
which can display 28 copies of up to 2 different proteins. The third
platform uses a caseinolytic protease (Clp) which can display 28 copies
of up to two different proteins.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
<bullet> Malaria vaccinology.
Competitive Advantages:
<bullet> Pre-clinical data indicates that nanoparticles displaying
the malaria circumsporozoite protein (CSP) confer 100% sterilizing
immunity in mice.
Developmental Stage:
<bullet> Pre-Clinical.
Inventors: Dr. Niraj H. Tolia, Dr. Dashuang Shi, Mr. Vu Nguyen, and
Dr. Thayne H. Dickey, all of NIAID.
Publications: Shi D, et al. A Plasmodium-derived nanoparticle
vaccine elicits sterile protection against malaria in mice. Nat
Microbiol. 2026;11(1):67-80. doi:10.1038/s41564-025-02209-y.
Intellectual Property: HHS Reference No. E-182-2024-0. U.S.
Provisional Patent Application No. 63/695,288, filed on September 16,
2024, and PCT Patent Application No. PCT/US2025/046419, filed on
September 15, 2025.
Licensing Contact: To license this technology, please contact Chris
Kornak at 240-565-2632, or <a href="/cdn-cgi/l/email-protection#ed8e859f849ec386829f838c86ad838485c38a829b"><span class="__cf_email__" data-cfemail="16757e647f65387d796478777d56787f7e38717960">[email protected]</span></a>, and reference E-182-
2024-0.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please
[[Page 11330]]
contact Chris Kornak at 240-565-2632, or <a href="/cdn-cgi/l/email-protection#83e0ebf1eaf0ade8ecf1ede2e8c3edeaebade4ecf5"><span class="__cf_email__" data-cfemail="07646f756e74296c687569666c47696e6f29606871">[email protected]</span></a>.
Dated: March 3, 2026.
Surekha Vathyam,
Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2026-04532 Filed 3-6-26; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 9, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.